课题基金 / 基金详情

项目摘要

项目成果

GUSTAVO WALTER LEONE的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The Hollings Cancer Center (HCC) Cell Evaluation & Therapy (CET) Shared Resource offers HCC investigators comprehensive analytic flow cytometry and high-speed cell sorting services and the capacity to generate human cellular and tissue-based products for use in translational research. The mission of the CET Shared Resource is to provide an integrated platform where HCC users can evaluate pre-clinical or clinical experimental data in a cell-specific manner and use the cell-manufacturing facility to bring the cellular product to patients. Directed by Kevin F. Staveley-O'Carroll, MD, PhD, with two Associate Directors, Amanda C. LaRue, PhD and Shikhar Mehrotra, PhD, this facility provides extensive expertise, an active educational platform, and development of new methodologies within the facility. The specific objectives of the HCC CET Shared Resource are to provide: • Multi-parametric and multi-laser measurements including apoptosis, cell proliferation, cell cycle distribution, and immunophenotyping, as well as detection of intracellular proteins, membrane perturbations, and bioactive molecules. • Expanded cell therapy and gene therapy-based bio-therapeutic products for Phase I and II clinical studies employing current cGMP as required by federal regulations. • Immune monitoring services to evaluate the immune response in patients and provide data for basic laboratory experiments. • Regulatory expertise in the preparation of cell and possibly gene therapy based INDs. • High-speed cell sorting based on cell surface marker immunostaining and/or side-population staining. • Consultation and assistance concerning experimental design, sample preparation, and data analysis. • Training in the use of routine flow cytometric technology and analytical equipment. • Advanced training in novel flow cytometric assays that are new and/or specific to HCC researchers' applications. • New methods to assist HCC members in performing cutting-edge research. CET-supported experiments during the current CCSG project period have led to the success of more than 18 NCI-funded research project grants and more than 100 peer-reviewed publications.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Leaders of Scientific Research Programs
Administration
LIPIDOMICS SHARED RESOURCE GROUP
Clinical Trials Office and Data & Safety Monitoring
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: